Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical...
02 oct. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
27 sept. 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
25 sept. 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
24 sept. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides an Update on the FDA Import Alert

MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
17 sept. 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
29 août 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
20 août 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

Positive Results from Cohort 5 of Phase 1b TrialCompany Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose MADISON, Wis., Aug. 20, 2018 (GLOBE...
13 août 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
10 août 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update

MADISON, Wis., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB)(“Cellectar or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development...

Page précédente

Page suivante